Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 4/20 | 0.37 |
| ▸ | GLS | O94925 | 1/20 | 0.37 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23165117 | 0.86 | ATR (0.46) | CA1CA2NAMPTMETAP1CYP17A1 | |
| SCHEMBL14507524 | 0.83 | CA1 (0.41) | CA1CA2NAMPTMETAP1CYP17A1 | |
| SCHEMBL289636 | 0.83 | LCK (0.41) | CA1CA2NAMPTMETAP1CYP17A1 | |
| SCHEMBL528069 | 0.81 | NPC1 (0.41) | CA1CA2CYP17A1ATRLCK | |
| SCHEMBL13955004 | 0.81 | ATR (0.41) | CA1CA2NAMPTMETAP1CYP17A1 | |
| SCHEMBL19455034 | 0.81 | CA1 (0.43) | CA1CA2NAMPTCYP17A1ATR | |
| SCHEMBL15235889 | 0.79 | CYP17A1 (0.39) | CA1CA2NAMPTMETAP1CYP17A1 | |
| SCHEMBL18071028 | 0.79 | CA1 (0.39) | CA1CA2NAMPTMETAP1CYP17A1 | |
| SCHEMBL3114014 | 0.79 | CA1 (0.42) | CA1CA2NAMPTMETAP1CYP17A1 | |
| SCHEMBL28254321 | 0.79 | CSNK2A2 (0.47) | NAMPTCYP17A1LCKGLSCSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4578451-A2 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | Novartis AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| EP-4214210-B1 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | NOVARTIS AG (CH) | 2025-04-09 | — | — | EP | disclosed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| CN-116615425-A | Compounds and compositions as Sppl2a inhibitors | 诺华股份有限公司 | 2023-08-18 | — | — | CN | disclosed |
| EP-4214210-A1 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | Novartis AG (CH) | 2023-07-26 | — | — | EP | disclosed |
| CN-113024536-B | 5-aminothiazole methanamide compound containing pyrimidine-piperazine ring and preparation method and application thereof | 湖南师范大学 | 2022-05-27 | — | — | CN | disclosed |
| CN-113024536-A | 5-aminothiazole methanamide compound containing pyrimidine-piperazine ring and preparation method and application thereof | 湖南师范大学 | 2021-06-25 | — | — | CN | disclosed |
| CN-104640858-A | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | HOFFMANN LA ROCHE | 2015-05-20 | — | — | CN | disclosed |
| CN-102933572-B | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | HOFFMANN LA ROCHE | 2015-01-07 | — | — | CN | disclosed |
| CN-103124724-A | Arylcyclopropylamine-based demethylase inhibitors of LSD1 and their medical use | ORYZON GENOMICS SA | 2013-05-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | SPPL2A, SPPL2B, BACE1 | CA1 633/4885CA2 1343/4885NAMPT 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.